Ionis Pharmaceuticals
IONS
341 hedge funds and large institutions have $3.75B invested in Ionis Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 106 increasing their positions, 119 reducing their positions, and 38 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
55% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 38
5% more funds holding
Funds holding: 325 → 341 (+16)
1.03% more ownership
Funds ownership: 86.24% → 87.27% (+1%)
8% less capital invested
Capital invested by funds: $4.08B → $3.75B (-$333M)
11% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 119
43% less call options, than puts
Call options by funds: $14.9M | Put options by funds: $26.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$42.2M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$31.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.7M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$18.6M |
| 5 |
BlackRock
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$45.5M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$45M |
| 3 |
Rockefeller Capital Management
New York
|
-$41.6M |
| 4 |
JP Morgan Chase
New York
|
-$36.1M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$34.9M |
IONS Hedge Fund Activity: Q4 2021 in Review
341 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2021, worth a combined $3.75B — down 8.2% from $4.08B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new IONS positions and 38 closed out — a net gain of 21 holders — while 106 added to existing stakes and 119 trimmed.
The largest buyer was Millennium Management, adding an estimated $42.2M. The largest seller was ClearBridge Investments, cutting an estimated $45.5M.
- 341 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2021, up from 325 in Q3 2021.
- Funds reported $3.75B of Ionis Pharmaceuticals stock for Q4 2021, down 8.2% quarter-over-quarter.
- 59 funds opened new Ionis Pharmaceuticals positions in Q4 2021 and 38 closed out, a net change of +21 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2021 was Millennium Management, an estimated $42.2M added.
- The largest Ionis Pharmaceuticals seller in Q4 2021 was ClearBridge Investments, an estimated $45.5M sold.
Based on aggregated 13F filings for Q4 2021.